CLICK TO SHARE
Merck’s new medication, molnupiravir, works by inhibiting the mechanisms by which the virus replicates.
As I have noted many times before, an effective COVID-19 response plans will include focus in effective and inexpensive treatments.
Merck plans to request emergency approval for an experimental oral COVID-19 antiviral drug, molnupiravir, after a late-stage trial indicated an approximate 50% risk reduction for hospitalization or death among patients with mild to moderate COVID-19.
An interim analysis, stemming from the Phase 3 MOVe-OUT trial, indicated 7.3% of patients who received molnupiravir were hospitalized or had died about a month later, compared with 14.1% of patients receiving a placebo. The company also reported no deaths in the treatment group, versus eight deaths in the placebo group.
“Merck plans to submit an application for Emergency Use Authorization (EUA) to the U.S. FDA as soon as possible based on these findings and plans to submit marketing applications to other regulatory bodies worldwide,” the company said Friday.
Watch the video:
Chemist's PSA in the face of a likely coming misinformation storm: No, Merck's molnupiravir is NOT repackaged ivermectin — they are vastly different in structure and intended action. pic.twitter.com/iIXBSZrwbw
— Chris Cramer (@CRO_Cramer) October 1, 2021
If you don't see any comments yet, congrats! You get first comment. Be nice and have fun.
CLICK TO SHARE